1 day Ago By ABMN Staff
Virtu Financial LLC purchased a new position in CervoMed Inc. ( NASDAQ:CRVO – Free Report ) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,224 shares of the company’s stock, valued at approximately $26,000.
A number of other institutional investors have also recently made changes to their positions in CRVO. Perigon Wealth Management LLC bought a new stake in CervoMed in the 4th quarter worth $147,000. Cornerstone Wealth Management LLC purchased a new stake in shares of CervoMed during the fourth quarter worth about $48,000.
Barclays PLC grew its stake in shares of CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after purchasing an additional 5,919 shares during the last quarter.
Geode Capital Management LLC increased its holdings in CervoMed by 13.9% during the 3rd quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock valued at $1,678,000 after purchasing an additional 14,042 shares during the period.
Finally, State Street Corp raised its position in CervoMed by 28.1% during the 3rd quarter. State Street Corp now owns 104,456 shares of the company’s stock valued at $1,525,000 after purchasing an additional 22,903 shares during the last quarter.
Hedge funds and other institutional investors own 25.15% of the company’s stock. Analysts Set New Price Targets A number of brokerages recently commented on CRVO.
Canaccord Genuity Group raised their price target on CervoMed from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, March 18th.
Chardan Capital raised shares of CervoMed from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Thursday, March 13th. Roth Mkm increased their price target on shares of CervoMed from $15.
00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, March 18th. Morgan Stanley restated an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th.
Finally, HC Wainwright downgraded CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.
com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.50. CervoMed Trading Up 9.
1 % Shares of NASDAQ:CRVO opened at $9.98 on Wednesday. The stock has a fifty day simple moving average of $4.
29 and a two-hundred day simple moving average of $7.42. CervoMed Inc.
has a 12-month low of $1.80 and a 12-month high of $25.92.
The stock has a market capitalization of $86.86 million, a price-to-earnings ratio of -4.92 and a beta of 1.
84. CervoMed ( NASDAQ:CRVO – Get Free Report ) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.
80) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.13).
The company had revenue of $2.16 million for the quarter, compared to the consensus estimate of $1.51 million.
CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%.
As a group, equities research analysts predict that CervoMed Inc. will post -1.88 EPS for the current year.
CervoMed Profile ( Free Report ) CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. Further Reading Want to see what other hedge funds are holding CRVO? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for CervoMed Inc. ( NASDAQ:CRVO – Free Report ). Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.
com's FREE daily email newsletter ..
_8.jpg?itok=wp-xhXRB)
